FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to ophthalmology, and aims at preventing or treating dry eye syndrome or dry eye symptoms and/or symptoms. Sterile aqueous ophthalmic solution contains from 0.05 % to 0.5 % (w/w) N-(N-acetylcysteinyl)chitosan or its pharmaceutically acceptable salt in a carrier solution, wherein N-(N-acetylcysteinyl)chitosan has content of free thiol groups in amount of 80 mcmole/g of polymer to 280 mcmole/g of polymer. For preventing or treating dry eye syndrome or dry eye symptoms and/or symptoms, an effective amount of the above sterile aqueous ophthalmic solution is administered into a subject. Another embodiment is a container containing said sterile aqueous ophthalmic solution, wherein the solution is in an atmosphere with oxygen content of 1.5 % or less.
EFFECT: use of the group of inventions provides an effective, safe, well-tolerated and long-term stability ophthalmic solution, allowing to increase the prevention or treatment of dry eye syndrome or dry eye symptoms and/or symptoms.
18 cl, 10 dwg, 9 tbl, 12 ex
Title | Year | Author | Number |
---|---|---|---|
USE IN THERAPY OF A STERILE AQUEOUS OPHTHALMIC SOLUTION | 2016 |
|
RU2741912C2 |
HYDROGEN SULPHIDE RELEASING POLYMER COMPOUNDS | 2017 |
|
RU2768716C2 |
APPLICATION OF POLYMERS | 2007 |
|
RU2432181C2 |
METHODS AND COMPOSITIONS FOR TREATING DRY EYE DISEASE AND OTHER EYE DISEASES | 2016 |
|
RU2691412C2 |
OPHTHALMOLOGICAL COMPOSITIONS | 2017 |
|
RU2756758C2 |
OPHTHALMIC COMPOSITION | 2012 |
|
RU2625301C2 |
ANTIPERSPIRANT COMPOSITIONS | 2006 |
|
RU2416392C2 |
OPHTHALMIC COMPOSITION WITH VISCOSITY ENHANCEMENT SYSTEM HAVING TWO DIFFERENT VISCOSITY ENHANCING AGENTS | 2012 |
|
RU2601115C2 |
OPHTHALMOLOGIC GEL AND METHOD OF ITS PREPARATION | 2007 |
|
RU2340327C1 |
CHITOSAN-CONTAINING COMPOSITION STERILIZED BY HEATING, AS WELL AS METHOD FOR PRODUCTION THEREOF | 2015 |
|
RU2712271C2 |
Authors
Dates
2019-05-23—Published
2015-05-04—Filed